Literature DB >> 22417172

Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers.

Jing Xu1, Saya Igarashi, Motoko Sasaki, Takashi Matsubara, Norihide Yoneda, Kazuto Kozaka, Hiroko Ikeda, Jihun Kim, Eunsil Yu, Osamu Matsui, Yasuni Nakanuma.   

Abstract

BACKGROUND AND AIMS: Intrahepatic cholangiocarcinomas (ICCs) are usually adenocarcinomas with fibrotic and hypovascular stroma. Intrahepatic cholangiocarcinomas in cirrhosis and precirrhotic liver (ICC-cirrhosis) are increasingly being diagnosed, and can display hypervascular enhancement resembling a hepatocellular carcinoma on dynamic imaging.
METHODS: In this study using ICC-cirrhosis (71 cases), ICC with non-specific reactive changes (ICC-reactive) (72 cases) and the cholangiocarcinoma component of combined hepatocellular cholangiocarcinoma (HCC-ICC) (30 cases), we tried to compare the tumour vasculature.
RESULTS: It was found that ICC-cirrhosis and the cholangiocarcinoma component of HCC-ICC showed a higher density of arteries and microvessels (1.59 ± 0.58/mm(2) (mean ± SD) and 140 ± 43/mm(2) in ICC-cirrhosis and 1.74 ± 0.67/mm(2) and 131 ± 46/mm(2) in the cholangiocarcinoma component of HCC-ICC) than in ICC-reactive (1.26 ± 0.61/mm(2) and 103 ± 45/mm(2) ). Dynamic computed tomography (CT) and magnetic resonance imaging (MRI) showed that a majority of ICC-cirrhosis displayed strong hypervascular enhancement, whereas one-third of ICC-reactive each showed strong, weak and no or minimal enhancement respectively. The increased vascular density was positively correlated with enhanced arterial phase of dynamic CT and MRI.
CONCLUSION: The density of arteries and microvessels of ICC-cirrhosis was higher than that in ICC-reactive and comparable to that in the cholangiocarcinoma component of HCC-ICC, and the higher density of arteries and microvessels in ICC may be responsible for the hypervascular enhancement of ICC-cirrhosis.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2012        PMID: 22417172     DOI: 10.1111/j.1478-3231.2012.02783.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  28 in total

1.  Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.

Authors:  Rihyeon Kim; Jeong Min Lee; Cheong-Il Shin; Eun Sun Lee; Jeong Hee Yoon; Ijin Joo; Seong Ho Kim; Inpyeong Hwang; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2015-09-15       Impact factor: 5.315

2.  Different MR features for differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma according to tumor size.

Authors:  Ting Ni; Xiao-Sha Shang; Wen-Tao Wang; Xin-Xing Hu; Meng-Su Zeng; Sheng-Xiang Rao
Journal:  Br J Radiol       Date:  2018-06-05       Impact factor: 3.039

3.  Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-enhanced MRI.

Authors:  Jieun Koh; Yong Eun Chung; Ji Hae Nahm; Ha Yan Kim; Kyung-Sik Kim; Young Nyun Park; Myeong-Jin Kim; Jin-Young Choi
Journal:  Eur Radiol       Date:  2015-05-23       Impact factor: 5.315

4.  Performance of Gd-EOB-DTPA-enhanced MRI for the diagnosis of LI-RADS 4 category hepatocellular carcinoma nodules with different diameters.

Authors:  Qi Tang; Cong Ma
Journal:  Oncol Lett       Date:  2018-06-04       Impact factor: 2.967

5.  Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI.

Authors:  Jiyoung Hwang; Young Kon Kim; Ji Hye Min; Seo-Youn Choi; Woo Kyung Jeong; Seong Sook Hong; Hyun-Joo Kim; Soohyun Ahn; Hyeon Seon Ahn
Journal:  Eur Radiol       Date:  2017-05-12       Impact factor: 5.315

6.  Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma?

Authors:  Massimo Galia; Adele Taibbi; Daniele Marin; Alessandro Furlan; Marco Dioguardi Burgio; Francesco Agnello; Giuseppe Cabibbo; Bernard E Van Beers; Tommaso Vincenzo Bartolotta; Massimo Midiri; Roberto Lagalla; Giuseppe Brancatelli
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

Review 7.  Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

8.  Comparison of clinicopathological characteristics between cirrhotic and non-cirrhotic patients with intrahepatic cholangiocarcinoma: A large-scale retrospective study.

Authors:  Lei Yuan; Xianwu Luo; Xinyuan Lu; Bin Yi; Kaijian Chu; Quanyu Cai; Xiaoqing Jiang
Journal:  Mol Clin Oncol       Date:  2017-08-22

9.  Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.

Authors:  Daniel R Ludwig; Tyler J Fraum; Roberto Cannella; David H Ballard; Richard Tsai; Muhammad Naeem; Maverick LeBlanc; Amber Salter; Allan Tsung; Anup S Shetty; Amir A Borhani; Alessandro Furlan; Kathryn J Fowler
Journal:  Abdom Radiol (NY)       Date:  2019-06

Review 10.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.